CDH2 and cancer: In some in vitro cancer models, such as melanoma, cervical carcinoma, and breast cancer, the role of EMT markers (i.e., N-cadherin, Vimentin, Snail, and Twist) as promoters of cell motility and increased resistance to an anti-cancer treatment has been described [27,28].